Immunotherapy / TIGIT inhibitorPhase 3 trialInvestigational
Tiragolumab
How it works
Tiragolumab is a monoclonal antibody that blocks the TIGIT receptor on immune cells, allowing them to recognize and attack cancer cells. It also triggers the release of cytokines that recruit immune cells to the tumor site.
Cancer types
Pancreatic Cancer— All patients
Efficacy
In clinical trials, tiragolumab improved overall survival in patients with pancreatic cancer, with a median survival of approximately 10.8 months.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.